Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

The Chinese University of Hong Kong | China

Author Profile

Scopus

Dr. Wenjin Wang 🌟🔬

Postdoctoral Researcher | Tumor Photodynamic Therapy Expert | Biomolecular Phase Separation Investigator

Research Interests

  1. Tumor Photodynamic Therapy (PDT) 💡🎯
    • Design and synthesis of novel photosensitizers for PDT.
    • Development of tumor-targeted PDT using tumor-responsive AIE (Aggregation-Induced Emission) photosensitizers.
  2. Regulation of Biomolecular Phase Separation 🧬⚛️
    • Investigation into the phase separation behaviors of biomolecules like proteins and nucleic acids.
    • Modulation of these processes with chemical molecules to enhance understanding of intracellular organization and function.

Professional Experience

  • Postdoctoral Researcher 🏢
    The Chinese University of Hong Kong, Shenzhen (07/2022–Present)

    • Research on bioapplications of AIE materials under Prof. Ben Zhong Tang.
  • Biochemical Engineer 🧪
    Shenzhen BGI Research Institute (10/2017–09/2018)

    • Designed and optimized unnatural nucleotides for sequencing applications.
  • Laboratory Assistant 🔬
    Peking University Shenzhen Graduate School (11/2016–10/2017)

    • Focused on unnatural amino acids and asymmetric carbene O-H bond insertion catalysis by myoglobin proteins.
  • Research Associate 💊
    Tianjin Institute of Pharmaceutical Research (08/2014–11/2016)

    • Developed new hypoglycemic drugs through innovative designs and research.

Education

  • Ph.D. in Chemical Biology 🧫
    Sun Yat-Sen University (09/2018–06/2022)

    • Thesis: Antitumor mechanisms of metal complexes and their regulation on biomolecular phase separation behavior.
  • M.S. in Pharmacy 💊
    Tianjin Medical University (09/2012–06/2015)

    • Research: Development of SGLT2 inhibitors and hypoglycemic activity evaluation.
  • B.S. in Pharmacy 🏥
    Tianjin Medical University (09/2008–06/2012)

Grants and Funding 💰📚

  1. National Natural Science Foundation of China
    • Ruthenium Complexes and Lipid Phase Separation in Antitumor Research (2024–2026, RMB 300K, Principal Investigator).
  2. China Postdoctoral Science Foundation
    • GGT-Activated AIE Photosensitizers for Tumor Photodynamic Therapy (2022–2025, RMB 80K, Principal Investigator).
  3. Shenzhen Medical Research Fund
    • Manipulable Aggregation of AIE Photosensitizers for Enhanced Tumor PDT (2025–2027, RMB 800K, Principal Investigator).
  4. National Natural Science Foundation of China
    • Phase Separation Mechanism of Antitumor Phosphor Metal Complexes (2022–2025, RMB 630K, Major Participant).
  5. Yunnan Province Science and Technology Plan
    • Aggregate Induced Luminescence in Biomass Resources (2024–2026, RMB 2000K, Major Participant).

Awards and Honors 🏆✨

  • Excellent Postdoctoral Doctor (Shenzhen, 12/2023).
  • National Scholarship for Doctoral Students (12/2021).
  • “Fran” Excellent Thesis Scholarship (Second Class, Sun Yat-sen University, 11/2021).
  • Excellent Wall Poster Award (32nd Academic Annual Meeting, Chinese Chemical Society, 04/2021).

Key Contributions 📈

Dr. Wang’s groundbreaking research combines innovative photodynamic therapies and the manipulation of biomolecular phase separation, driving advancements in cancer treatment and molecular biology.

📊🔬NOTABLE PUBLICATION:
  • Title: Multi-Stimuli-Responsive and Cell Membrane Camouflaged Aggregation-Induced Emission Nanogels for Precise Chemo-photothermal Synergistic Therapy of Tumors
    • Authors: Zhang, L.; Wang, Z.; Zhang, R.; … Zhao, Z.; Tang, B.Z.
    • Journal: ACS Nano
    • Year: 2023

 

  • Title: Multi-site isomerization of synergistically regulated stimuli-responsive AIE materials toward multi-level decryption
    • Authors: Zhong, W.; Zhang, J.; Lin, Y.; … Cai, X.-M.; Tang, B.Z.
    • Journal: Chemical Science
    • Year: 2024

 

  • Title: Chromene-based BioAIEgens: ‘in-water’ synthesis, regiostructure-dependent fluorescence and ER-specific imaging
    • Authors: Cai, X.-M.; Lin, Y.; Zhang, J.; … Zhao, Z.; Tang, B.Z.
    • Journal: National Science Review
    • Year: 2023

 

  • Title: Natural Acceptor of Coumarin-Isomerized Red-Emissive BioAIEgen for Monitoring Cu²⁺ Concentration in Live Cells via FLIM
    • Authors: Cai, X.-M.; Li, S.; Wang, W.-J.; … Zhao, Z.; Tang, B.Z.
    • Journal: Advanced Science
    • Year: 2024

 

  • Title: Room Temperature Phosphorescent Nanofiber Membranes by Bio-Fermentation
    • Authors: Nie, X.; Gong, J.; Ding, Z.; … Qiu, Z.; Tang, B.Z.
    • Journal: Advanced Science
    • Year: 2024

Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Shanghai University of Traditional Chinese Medicine | China

AUTHOR PROFILE

Scopus

📚 EARLY ACADEMIC PURSUITS

Xin Xin’s academic journey is rooted in the integration of Traditional Chinese Medicine (TCM) with Western medicine, particularly focusing on reproductive health and gynecology. He obtained a Bachelor of Science in Chinese Medicine from Shandong University of Traditional Chinese Medicine. His academic foundation continued to expand as he pursued an MD in Gynecology of Traditional Chinese Medicine, further honing his expertise in reproductive diseases. Xin is currently working towards his PhD in Clinical Chinese Medicine Integrated with Western Medicine at Shanghai University of Traditional Chinese Medicine, under the guidance of Advisor Jinfu Zhang.

💼 PROFESSIONAL ENDEAVORS

Xin Xin’s professional career is centered on bridging the gap between traditional and modern medical approaches. He is particularly involved in the clinical and mechanistic research of reproductive diseases, with a primary focus on polycystic ovary syndrome (PCOS). His work aims to enhance diagnostic methods and treatment approaches through a combined understanding of TCM and Western medicine. Xin has contributed significantly to clinical studies and investigations, with his academic path guided by prominent scholars in the field, including Dr. Fang Lian and Dr. Haicui Wu during his MD program at Shandong University.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Xin Xin’s research is notable for its emphasis on the pathogenesis, diagnosis, and treatment of reproductive diseases, with a particular focus on PCOS. He has undertaken several groundbreaking projects, one of which explores the expression of long non-coding RNAs (lncRNA) in follicular fluid exosomes of patients with obesity and PCOS using high-throughput sequencing technology. This research represents an effort to better understand the molecular mechanisms behind PCOS and to uncover novel biomarkers for early detection and intervention.

Another area of Xin’s research explores the role of Bone Morphogenetic Protein 6 (BMP6) in regulating Pentraxin 3 expression in human granulosa lutein cells in women with PCOS. His studies are pivotal in uncovering molecular markers and pathways that could lead to more effective therapeutic strategies.

🌟 IMPACT AND INFLUENCE

Xin Xin’s work has garnered attention within the scientific community due to his innovative approach of combining traditional Chinese medicine with Western medical techniques. His research aims to contribute to the development of a more holistic and comprehensive understanding of reproductive diseases. By investigating both the molecular and clinical aspects of PCOS, Xin is pushing boundaries in reproductive health research. His work has the potential to change how clinicians approach the treatment of polycystic ovary syndrome, a condition that affects millions of women worldwide.

📑 ACADEMIC CITES

Although his research is relatively recent, Xin Xin’s work is beginning to attract attention in the academic community. His publications on the expression of lncRNAs and BMP6 in PCOS are contributing to the growing body of knowledge on this common reproductive disorder. These publications are expected to increase in citations as they influence future studies and clinical approaches. His articles, including “Exploring lncRNA expression in follicular fluid exosomes of patients with obesity and polycystic ovary syndrome” (2024), and “Bone Morphogenetic Protein 6 Induces Downregulation of Pentraxin 3 Expression in Human Granulosa Lutein Cells in Women With Polycystic Ovary Syndrome” (2024), are already making a mark in reproductive health research.

🌱 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Xin Xin is poised to continue his impactful contributions to the field of reproductive medicine. With a focus on integrating TCM with Western medical practices, his future research may lead to the development of novel therapeutic modalities for PCOS and other reproductive diseases. He is likely to remain an influential figure in the field of gynecology, particularly in areas that explore the intersections between traditional and modern approaches to healthcare. His research has the potential to influence both clinical practices and medical education, paving the way for new, more integrated methods of treating complex reproductive health conditions.

In the coming years, Xin Xin’s work will likely expand into further clinical trials and studies, contributing to the refinement of treatments for women with PCOS, and potentially providing a more personalized and effective approach to reproductive medicine globally.

✨Conclusion:

Xin Xin’s academic and professional journey stands as a testament to the growing importance of integrating traditional and modern medical practices in addressing complex health conditions. His dedicated research in reproductive medicine, particularly focusing on polycystic ovary syndrome (PCOS), has already made valuable contributions to understanding its pathogenesis and improving diagnostic and therapeutic methods. By exploring innovative molecular mechanisms and combining high-throughput sequencing technology with traditional Chinese medicine, Xin is laying the groundwork for a more holistic approach to treating reproductive diseases.

📊🔬NOTABLE PUBLICATION:
  • Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching
    • Authors: Dong, L., Lian, F., Wu, H., Yu, X., Xin, X.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2022

 

  • The effect of large follicle puncture and aspiration on the outcomes of IVF-ET in patients with asynchronized follicles under the long GnRH-a protocol: a retrospective cohort study
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2023

 

  • Effect of human chorionic gonadotropin injection before frozen-thawed embryo transfer: A retrospective cohort study
    • Authors: Xin, X., Dong, L., Guan, L., Li, J., Lian, F.
    • Journal: Medicine (United States)
    • Year: 2023

 

  • Clinical Efficacy and Mechanism of Erzhi Tiangui Prescription in Treatment of Patients with Repeated Implantation Failure of Kidney Deficiency Syndrome Based on sPD-1 and Th17/Treg Cytokines
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: Chinese Journal of Experimental Traditional Medical Formulae
    • Year: 2023

 

  • Total knee arthroplasty in patients with Klippel Trenaunay syndrome and knee osteoarthritis: A case report and a literature review
    • Authors: Li, J., Lv, G., Han, Z., Xin, X.
    • Journal: Medicine (United States)
    • Year: 2024